key: cord-0880783-bummo8u2 authors: Liu, Mei; Hu, Ruixue; Jiang, Xuqin; Mei, Xiaodong title: Coagulation dysfunction in patients with AECOPD and its relation to infection and hypercapnia date: 2021-03-25 journal: J Clin Lab Anal DOI: 10.1002/jcla.23733 sha: 1de450a2e8e0188ef9c471d82f5656ffb7c9ca73 doc_id: 880783 cord_uid: bummo8u2 BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) often have coagulation abnormalities. However, the factors that lead to coagulation dysfunction in acute exacerbation of COPD (AECOPD) remain insufficiently explored. This study aimed to investigate the factors affecting coagulation status in patients with COPD and their influence on thrombosis. METHODS: Data of COPD patients, including 135 cases in acute exacerbation stage and 44 cases in stable stage from Nov 2016 to Nov 2019 in our hospital, were collected. Healthy people (n = 135) were enrolled as the controls. The coagulation parameters, blood gas indexes and blood routine examination results were collected and analyzed. RESULTS: White blood count (WBC), neutrophil count, neutrophil percentage (N%), platelet (PLT), prothrombin time (PT), international normalized ratio (INR), fibrinogen (FIB), and activated partial thromboplastin time (APTT) increased, plasma thrombin time (TT) decreased in AECOPD group compared with the control group. In AECOPD group, PT, APTT, and FIB were positively correlated with neutrophils and C‐reaction protein levels. PT was positively correlated with PCO2 and negatively with pH. Thrombosis was observed in five acute exacerbation and three stable stage COPD patients. CONCLUSIONS: Patients with AECOPD presented abnormal coagulation status, which was correlated to infection and hypercapnia and might be potentially the risk factor of thrombosis. patients developed respiratory failure often have circulatory and coagulation dysfunction, 3, 4 which was considered the cause of thrombosis events in the patients. 3 The coagulation abnormality could cause pulmonary embolism, 5 myocardial infarction, cerebral infarction, and other thrombosis events in COPD patients. 6 These events often lead to extended hospital stay, poor prognosis, and even increased mortality. The coagulation dysfunction and its role in COPD have been explored for years. Actually, the presence of coagulation abnormalities in smokers had been reported long ago as blood coagulation abnormalities existed in smokers and even in the passive smokers. 7 The factors involved in abnormal coagulation in COPD have also been reported. For example, acidosis could affect the coagulation status in COPD patients. 8 Respiratory bacterial infections, lipoprotein-associated phospholipase A2, myeloperoxidase, and vascular endothelial growth factor could change the coagulation status, which could be the high risk factors of thrombotic events. 9 However, the factors lead to coagulation dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) remain insufficient explored. Obviously, finding out the causes of coagulation dysfunction in AECOPD would help control the abnormality and secondary thrombosis risks. In this study, the coagulation status in patients with COPD was investigated and some factors such as infection and hypercapnia were found to be related to the coagulation abnormality and thrombosis in those patients. A retrospective clinical study was performed to investigate the factors correlated to abnormal coagulation status in COPD. The study was designed to collect the data of patients with COPD who were in acute exacerbation stage and hospitalized in Affiliated Stable stage COPD (SCOPD) patients were those outpatients who had been diagnosed as COPD and no exacerbated symptoms. The controls were those who were in good general health with normal spirometry results, no history of cigarette smoking, had gastrointestinal polyps found in routine annual health examination, and planned to be operated. Exclusion criteria for both stages of COPD patients were a history of other pulmonary diseases, infective and inflammatory diseases, neoplastic pathologies, hematological, autoimmune, renal, gastrointestinal and hepatic diseases, and current use of anticoagulants. The study was approved by the Ethic Committee of Affiliated First Hospital, University of Science and Technology of China (number: 2020-P-080), and the study was designed in accordance with the Declaration of Helsinki. Demographic and baseline laboratory variables including blood routine, coagulation, blood gas, inflammatory indicators were collected. In AECOPD patients, these data were collected when the patient was admitted to hospital. Statistical analysis was performed using SPSS 22.0 (Statistical Package for the Social Sciences) statistical software. Data were presented as number of cases, mean ± standard deviation (SD), or median with interquartile range (IQR). All data were tested for normal distribution by Kolmogorov-Smirnov test. Data for normally distributed variables were expressed as medians with IQR and tested by Mann-Whitney test. Statistical analysis for multiple comparisons was analyzed by Kruskal-Wallis test for non-normally distributed variables. Pearson correlation was used to investigate the relationship between changes in coagulation and inflammatory markers. Statistical significance was defined as p < 0.05. A two-sided pvalue < 0.05 was considered significant for all analyses. A total of 135 AECOPD, 44 stable stage COPD patients, and 135 healthy controls were enrolled in this study. There were no significant differences in age, gender between AECOPD, SCOPD, and the control groups. No significant difference in disease course between AECOPD and SCOPD patients was found. The demographic characteristics of the subjects were summarized in Table 1 . Several cases of thrombosis were found in AECOPD and SCOPD patients, respectively. Data showed a significant difference in WBC count number and neutrophil percentage between AECOPD patients and the controls (p < 0.01). There was no significant difference in platelet count between any two of the three groups, while MPV decreased in AECOPD group (p < 0.01). No significant differences in WBC, N%, PLT were observed between the SCOPD and control group, as shown in The results of cross-correlation analysis between various factors and coagulation indexes in AECOPD patients are showed as Figure 1 . These changes could increase the blood viscosity and affect the blood coagulation. 12, 13 There are a wide range of interactions between coagulation and inflammations, 10, 13, 14 Coagulation dysfunction was rather common in AECOPD patients. 13, 17 In this observation, PT and APTT were significantly prolonged and FIB was evidently elevated in the AECOPD patients (Table 3 ). The prolongation of the coagulation parameters (such as APTT and PT) might be caused by the consumption of clotting factors, 18, 19 indicating that coagulation dysfunction in AECOPD patients is a complex process. D-dimer is an indicator of thrombosis 3 and suggested to be a prognostic biomarker for mortality in AECOPD. 20 In this study, a Some limitations existed in this study. Firstly, the exacerbation time before hospital admission of patients was not the same and the difference might affect coagulation parameter results. Secondly, each patient was given oxygen therapy after admission. The oxygen partial pressure data cannot be evaluated; therefore, the relationship between hypoxia and coagulation dysfunction cannot be analyzed. Thirdly, this was a retrospective study, and the number of enrolled subjects was limited. The controls were not absolute healthy people as they were found with polyps in routine physical examination and planned to be operated, although no symptoms and signs presented. Finally, the whole data of patients in hospital and later after discharge presenting the dynamic changes of coagulation status and occurrence of thrombosis could not be obtained. A more extensive study including more patients and more parameters is obviously needed. In summary, this study revealed that coagulation dysfunction existed in AECOPD patients. The abnormal coagulation was correlated to infection and hypercapnia and might be the main cause of thrombosis Note:: Data shown as median (interquartile range), P1 represents the difference between AECOPD and the controls, P2 represents AECOPD and SCOPD, P3 represents SCOPD and the controls. Abbreviations: AECOPD, acute exacerbation of chronic obstructive pulmonary disease; APTT, activated partial thromboplastin time; FIB, fibrinogen; INR, international normalized ratio; PT, prothrombin time; SCOPD, stable Chronic obstructive pulmonary disease; TT, plasma thrombin time. in the patients. To understand the cause of coagulation abnormality in COPD patients and take proper measurers might be of help in managing the disease. This work was supported by the Science and Technology Foundation of Anhui Province, China (1704f0804007). The authors declare that they have no conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. Xiaodong Mei https://orcid.org/0000-0002-7629-9200 Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories The prevalence and risk factors of venous thromboembolism in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease Air quality improvement during 2010 Asian games on blood coagulability in COPD patients The effect of COPD on the incidence and mortality of hospitalized patients with pulmonary embolism: a nationwide population-based study (2016-2018) The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease An in vitro analysis of the effect of acidosis on coagulation in chronic disease states -a thromboelastograph study Lipoprotein-associated phospholipase A2, myeloperoxidase and vascular endothelial growth factor -predictors of high vascular risk in respiratory bacterial infections Pulmonary thrombosis: a clinical pathological entity distinct from pulmonary embolism? COPD and risk of venous thromboembolism and mortality in a general population Acute exacerbations of COPD are associated with a prothrombotic state through plateletmonocyte complexes, endothelial activation and increased thrombin generation Coagulation markers as predictors for clinical events in COPD Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers Inflammation and coagulation Cross talk pathways between coagulation and inflammation Nebulized heparin and salbutamol versus salbutamol alone in acute exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation: a double-blind randomized controlled trial Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Coagulation dysfunction is associated with severity of COVID-19: a meta-analysis D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation Coagulation dysfunction in patients with AECOPD and its relation to infection and hypercapnia